1. Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma. (July 2016) Authors: Girotti, M.R.; Gremel, G.; Lee, R.; Galvani, E.; Rothwell, D.; Mandal, A.K.; Lim, K.H.J.; Saturno, G.; Furney, S.J.; Baenke, F.; Pedersen, M.; Smith, M.; Fusi, A.; Dhomen, N.; Brady, G.; Lorigan, P.; Dive, C.; Marais, R. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessing the interplay of RNA-fusion events with cancer driver mutations in melanoma patients. (July 2016) Authors: Mandal, A.; Girotti, M.R.; Dhomen, N.; Viros, A.; Gremel, G.; Galvani, E.; Baenke, F.; Lee, R.; Lim, K.H.J.; Lorigan, P.; Marais, R. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Gene-specific interactions between ultraviolet radiation and melanoma. (July 2016) Authors: Viriós, A.; Pedersen, M.; Furney, S.J.; Girotti, M.R.; Hogan, K.; Saturno, G.; Galvani, E.; Sanchez-Laorden, B.; Ng, C.; Reis-Filho, J.S.; Lorigan, P.; Cook, M.; Marais, R. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. (January 2018) Authors: Valpione, S.; Gremel, G.; Mundra, P.; Middlehurst, P.; Galvani, E.; Girotti, M.R.; Lee, R.J.; Garner, G.; Dhomen, N.; Lorigan, P.C.; Marais, R. Journal: European journal of cancer Issue: Volume 88(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy. (July 2016) Authors: Smith, M.P.; Brunton, H.; Rowling, E.J.; Girotti, M.R.; Marais, R.; Dummer, R.; Flaherty, K.T.; Cooper, Z.A.; Wargo, J.A.; Wellbrock, C. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Systematic longitudinal analysis of circulating tumour DNA in melanoma patients undergoing systemic therapy. (July 2016) Authors: Gremel, G.; Lee, R.J.; Girotti, M.R.; Garner, G.; Mandal, A.K.; Valpione, S.; Serra-Bellver, P.; Wood, S.; Fusi, A.; Dhomen, N.; Lorigan, P.; Marais, R. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models. (July 2016) Authors: Saturno, G.; Lopes, F.; Girotti, M.R.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Zambon, A.; Davies, L.; Johnson, L.; Preece, N.; Viros, A.; Pedersen, M.; McLeary, R.; Knight, R.; Lee, R.; Holovanchuk, D.; Fusi, A.; Lorigan, P.; Dhomen, N.; Marais, R.; Springer, C. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Tumour–microenvironment mediates resistance to immuno and targeted therapies in acral melanoma. (July 2016) Authors: Lee, R.; Girotti, M.R.; Khandelwal, G.; Baenke, F.; Viros, A.; Mandal, A.; Bridgeman, J.; Galvani, E.; Gremel, G.; Kalaitsidou, M.; Ashton, G.; Peset, I.; Smith, M.; Hawkins, R.; Fusi, A.; Miller, C.; Gilham, D.; Dhomen, N.; Lorigan, P.; Marais, R. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗